ZON

1-(1,2-benzoxazol-3-yl)methanesulfonamide

Created: 2010-11-26
Last modified:  2021-03-01

Help

Find related ligands:

Chemical Details

Formal Charge0
Atom Count22
Chiral Atom Count0
Bond Count23
Aromatic Bond Count10
2D diagram of ZON
Toggle HydrogenToggle Labels

Chemical Component Summary

Name1-(1,2-benzoxazol-3-yl)methanesulfonamide
SynonymsZonisamide
Systematic Name (OpenEye OEToolkits)1,2-benzoxazol-3-ylmethanesulfonamide
FormulaC8 H8 N2 O3 S
Molecular Weight212.226
TypeNON-POLYMER

Chemical Descriptors

TypeProgram Version Descriptor
SMILESACDLabs12.01O=S(=O)(N)Cc2noc1ccccc12
SMILESCACTVS3.370N[S](=O)(=O)Cc1noc2ccccc12
SMILESOpenEye OEToolkits1.7.0c1ccc2c(c1)c(no2)CS(=O)(=O)N
Canonical SMILESCACTVS3.370 N[S](=O)(=O)Cc1noc2ccccc12
Canonical SMILESOpenEye OEToolkits1.7.0 c1ccc2c(c1)c(no2)CS(=O)(=O)N
InChIInChI1.03 InChI=1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12)
InChIKeyInChI1.03 UBQNRHZMVUUOMG-UHFFFAOYSA-N

Drug Info: DrugBank

DrugBank IDDB00909 
NameZonisamide
Groups
  • investigational
  • approved
DescriptionZonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures.[L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This latter action may inhibit the uptake of the inhibitory neurotransmitter GABA while enhancing the uptake of the excitatory neurotransmitter glutamate.[L42530,L42535] Zonisamide represents an alternative for patients that remain refractory to established antiepileptic drugs. In 1989, it was approved for commercial use in Japan. The US and Europe approved it in 2000 and 2005, respectively.[A1379,A1383]
Synonyms
  • Zonisamida
  • Zonisamidum
  • 3-(Sulfamoylmethyl)-1,2-benzisoxazole
  • 1,2-Benzisoxazole-3-methanesulfonamide
  • Zonisamide
Brand Names
  • Zonisamide
  • Zonisamide Mylan
  • Zonisade
  • Zonegran
IndicationZonisamide capsules are indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy.[L42530] Zonisamide oral suspension is indicated as adjunctive therapy for the treatment of partial-onset seizures in adults and pediatric patients 16 years of age and older.[L42535]
Categories
  • Agents causing hyperkalemia
  • Amides
  • Anti-epileptic Agent
  • Antiarrhythmic agents
  • Anticonvulsants
ATC-Code
  • N03AX15
  • G01AE10
CAS number68291-97-4

Drug Targets

NameTarget SequencePharmacological ActionActions
Sodium channel protein type 1 subunit alphaMEQTVLVPPGPDSFNFFTRESLAAIERRIAEEKAKNPKPDKKDDDENGPK...unknowninhibitor
Sodium channel protein type 2 subunit alphaMAQSVLVPPGPDSFRFFTRESLAAIEQRIAEEKAKRPKQERKDEDDENGP...unknowninhibitor
Sodium channel protein type 3 subunit alphaMAQALLVPPGPESFRLFTRESLAAIEKRAAEEKAKKPKKEQDNDDENKPK...unknowninhibitor
Sodium channel protein type 4 subunit alphaMARPSLCTLVPLGPECLRPFTRESLAAIEQRAVEEEARLQRNKQMEIEEP...unknowninhibitor
Sodium channel protein type 5 subunit alphaMANFLLPRGTSSFRRFTRESLAAIEKRMAEKQARGSTTLQESREGLPEEE...unknowninhibitor
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL750
PubChem 5734, 11967800
ChEMBL CHEMBL750
ChEBI CHEBI:10127
CCDC/CSD VUXPUZ, TEZBAE, TEZGIR, TEZGIR01, SENPAG